Johnson & Johnson (NYSE:JNJ) Shares Down 1.1%

Johnson & Johnson (NYSE:JNJ - Get Free Report)'s stock price was down 1.1% during trading on Thursday . The company traded as low as $146.36 and last traded at $146.84. Approximately 1,937,967 shares were traded during trading, a decline of 74% from the average daily volume of 7,319,339 shares. The stock had previously closed at $148.53.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Morgan Stanley dropped their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an "equal weight" rating on the stock in a report on Wednesday, April 17th. Royal Bank of Canada dropped their target price on Johnson & Johnson from $181.00 to $175.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 17th. Bank of America decreased their price objective on Johnson & Johnson from $180.00 to $170.00 and set a "neutral" rating for the company in a research note on Wednesday, April 17th. StockNews.com upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, February 6th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Monday, April 15th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $175.86.

Johnson & Johnson Stock Performance

The business's 50-day simple moving average is $155.69 and its two-hundred day simple moving average is $155.47. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. The firm has a market cap of $353.80 billion, a price-to-earnings ratio of 9.15, a P/E/G ratio of 2.46 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.43% and a net margin of 45.26%. The business had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. During the same period in the prior year, the company posted $2.68 EPS. The business's quarterly revenue was up 2.3% on a year-over-year basis. As a group, sell-side analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be issued a $1.24 dividend. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.19. The ex-dividend date is Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a yield of 3.38%. Johnson & Johnson's dividend payout ratio is presently 29.68%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares of the company's stock, valued at approximately $22,099,078.32. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the business's stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the sale, the insider now owns 4,099,575 shares of the company's stock, valued at $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. First Citizens Financial Corp lifted its position in shares of Johnson & Johnson by 8.1% during the 3rd quarter. First Citizens Financial Corp now owns 8,599 shares of the company's stock worth $1,339,000 after buying an additional 645 shares during the last quarter. PineStone Asset Management Inc. boosted its position in shares of Johnson & Johnson by 190.5% in the 3rd quarter. PineStone Asset Management Inc. now owns 1,494,978 shares of the company's stock valued at $232,843,000 after purchasing an additional 980,297 shares during the period. Buckingham Capital Management Inc. increased its position in Johnson & Johnson by 6.5% during the third quarter. Buckingham Capital Management Inc. now owns 10,703 shares of the company's stock worth $1,667,000 after buying an additional 651 shares during the period. McKinley Carter Wealth Services Inc. lifted its stake in Johnson & Johnson by 0.6% in the third quarter. McKinley Carter Wealth Services Inc. now owns 18,860 shares of the company's stock valued at $2,937,000 after buying an additional 114 shares during the last quarter. Finally, OneAscent Financial Services LLC purchased a new position in shares of Johnson & Johnson during the third quarter worth approximately $838,000. 69.55% of the stock is owned by institutional investors and hedge funds.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.